Scientific report 2025 of the Cellular Therapy and Immunobiology Working Party (CTIWP)

The CTIWP continues to expand in parallel with the growing application of cell therapies across a wide range of diseases. Important achievement has been reached with more than 16,000 cases of CAR T reported to the EBMT Registry and continuing the  collaboration with other Working Parties and partner societies, including GoCART and the EHA. The EBMT-EHA European CAR T-cell Meeting represents an important focus on the new translational and clinical findings on cell therapies with distinguished speakers worldwide. 

The research activity of the CTIWP is broad and focuses on multiple factors influencing outcomes after transplants and CAR T-cell therapy. Two important studies on the outcomes of CAR T in older patients have been completed highlighting the feasibility of this innovative treatment regardless the limits of age. Furthermore a cross sectional survey on the fertility after CART demonstrated how fertility preservation is possible with more than 15 successful pregnancies reported in young patients treated with CART.